
CLAIMS

1. An antisense oligomer compound of formula (I):




(I)


or a pharmaceutically acceptable salt thereof,

where each Nu is a nucleobase which taken together forms a targeting sequence;

T is selected from:




;



; and  ; and

G is a cell penetrating peptide ("CPP") and linker moiety selected from:



-C(O)CH_2NH-CPP-R^a, and ,

wherein the CPP is attached to the linker moiety by an amide bond at the CPP carboxy terminus, R^a is attached to the CPP amino terminus by an amide bond wherein R^a is selected from H, acetyl, benzoyl, and stearoyl, and the CPP is selected from SEQ ID NOS: 5 – 21, and


wherein the targeting sequence is selected from:

a) SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) wherein Z is 23; and

b) SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) wherein Z is 23.


2. The antisense oligomer compound of claim 1, wherein G is selected from SEQ ID NOS: 24 OR 25.

3. The antisense oligomer compound of claims 1 or 2, wherein T is




.

4. The antisense oligomer compound according to any one of claims 1-3, wherein CPP-R^a is selected from:




,




,

and



.

5. The antisense oligomer compound according to any one of claims 1-3, wherein the CPP-R^a is 


.

6. The antisense oligomer compound according to any one of claims 1-5, wherein R^a is acetyl.

7. The antisense oligomer compound according to any one of claims 1-6, wherein the targeting sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.

8. The antisense oligomer compound according to any one of claims 1-6, wherein the targeting sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.

9. An antisense oligomer compound of formula (III):



(III) ,

or a pharmaceutically acceptable salt thereof, wherein:

each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) selected from:


a) SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) wherein Z is 23; and

b) SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) wherein Z is 23.

10. The antisense oligomer compound of claim 9, wherein the target sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.

11. The antisense oligomer compound of claim 9, wherein the target sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.


12. The antisense oligomer compound of claim 9, wherein the antisense oligomer compound is a compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) wherein the targeting sequence is SEQ ID NO: 3 (CTGAGCCGCTGGCAGATGCCTTGTC) and Z is 23.


13. The antisense oligomer compound of claim 9, wherein the antisense oligomer compound is a compound of formula (IV):



(IV)


or a pharmaceutically acceptable salt thereof, wherein each Nu is a nucleobase which taken together form a targeting sequence (5’ to 3’) wherein the targeting sequence is SEQ ID NO: 4 (GAGGAGATGGGTCCACCCACCTGGG) and Z is 23.

14. An antisense oligomer compound, or a pharmaceutically acceptable salt thereof, selected from:



(V a)


; and



(V b)

.


15. The antisense oligomer compound of claim 14, wherein the antisense oligomer compound is:



(V a)

.


16. The antisense oligomer compound of claim 14, wherein the antisense oligomer compound is:



(V b)


.

17. An antisense oligomer compound, or a pharmaceutically acceptable salt thereof, selected from:



(VI a)

; and



(VI b)

.

18. The antisense oligomer compound of any one of claims 1-17, wherein the antisense oligomer compound is a pharmaceutically acceptable salt of 0.6 HCl.

19. A pharmaceutical composition, comprising an antisense oligomer compound according to any one of claims 1-18 and a pharmaceutically acceptable carrier.

20. Use of an antisense oligomer compound according to any one of claims 1-18 or the pharmaceutical composition of claim 19 in the manufacture of a medicament for the treatment of Hutchinson- Gilford progeria syndrome (HGPS).